<SEC-DOCUMENT>0001193125-20-289568.txt : 20201110
<SEC-HEADER>0001193125-20-289568.hdr.sgml : 20201110
<ACCEPTANCE-DATETIME>20201110061928
ACCESSION NUMBER:		0001193125-20-289568
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201110
FILED AS OF DATE:		20201110
DATE AS OF CHANGE:		20201110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		201299540

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d822699d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 10, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d822699dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822699dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Reports Phase 1 Clinical Trial Data of Highly
Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020&nbsp;SITC&nbsp;Annual&nbsp;Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>- Initial monotherapy
results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment of relapsed/refractory malignancy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>- <FONT STYLE="white-space:nowrap">I-Mab</FONT> to host call for investors on November&nbsp;9 at 8:30am ET </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China, and GAITHERSBURG, MD.</B> &#150; November&nbsp;9, 2020 &#150; <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;)
(Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab
(also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma. The results were released in a poster entitled &#147;<I>A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-patient</FONT></FONT>
study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results&#148; </I>at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, on November&nbsp;9, 2020
(Abstract #385). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lemzoparlimab&nbsp;is a&nbsp;unique CD47 antibody&nbsp;that&nbsp;exerts strong anti-tumor activity while&nbsp;exhibiting a minimal
binding to red blood cells. It is designed to avoid&nbsp;severe anemia&nbsp;&#151;&nbsp;a&nbsp;common toxicity of CD47 antibodies of the same class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Lemzoparlimab was originally discovered and developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> as a globally competitive CD47 antibody and has
been uniquely designed to overcome&nbsp;the toxicity associated with this drug target,&#148; said&nbsp;Jingwu Zang, M.D., Ph.D., Founder, Honorary Chairman and Director of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;The&nbsp;initial
clinical results are consistent with the key differentiation of lemzoparlimab in terms of drug safety and the PK profile. These clinical advantages put&nbsp;lemzoparlimab&nbsp;in a highly competitive position among CD47 antibodies of the same
class.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;phase 1 study&nbsp;is an open-label, multi-center, multiple dose study&nbsp;conducted in&nbsp;two&nbsp;parts. The&nbsp;first part
is comprised of&nbsp;a&nbsp;single agent&nbsp;dose escalation&nbsp;followed by two&nbsp;separate combination regimens in an escalating dose range (Part 1b&nbsp;with&nbsp;pembrolizumab;&nbsp;Part 1c&nbsp;with&nbsp;rituximab). The second part is
a&nbsp;dose expansion study&nbsp;in the&nbsp;combination therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data to be presented at SITC include the&nbsp;initial results from
the&nbsp;single agent therapy (N=20),&nbsp;which&nbsp;is designed to determine the&nbsp;safety,&nbsp;tolerability,&nbsp;pharmacokinetics&nbsp;(PK),&nbsp;pharmacodynamics&nbsp;(PD)&nbsp;and anti-tumor activity&nbsp;of&nbsp;lemzoparlimab. The
key&nbsp;findings&nbsp;include:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lemzoparlimab was&nbsp;well tolerated&nbsp;up&nbsp;to 30&nbsp;mg/kg&nbsp;on a weekly basis without priming dosing
strategy. No&nbsp;dose-limiting toxicity and no&nbsp;clinical or laboratory evidence of hemolytic anemia&nbsp;were observed throughout. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant
&#147;sink effect&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One confirmed Partial Response (PR) was observed in the 30 mg/kg monotherapy cohort (N=3). The patient had failed
prior treatments with checkpoint inhibitors. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822699dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very encouraged by the safety and tolerability data that have emerged from the phase 1
trial,&#148; said&nbsp;Jordan Berlin, M.D.&nbsp;from&nbsp;Vanderbilt University,&nbsp;the principal investigator of the trial. &#147;It shows the promise of&nbsp;lemzoparlimab&nbsp;as a differentiated CD47 antibody for multiple cancers, and we look
forward to advancing&nbsp;the development of&nbsp;lemzoparlimab&nbsp;for patients with advanced solid tumors and hematologic malignancies.&#148; Dr.&nbsp;Berlin&nbsp;will present the data during the virtual poster sessions on November&nbsp;11, 2020 <FONT
STYLE="white-space:nowrap">5:15-5:45</FONT> p.m. EST and November&nbsp;13, 2020 <FONT STYLE="white-space:nowrap">4:40-5:10</FONT> p.m. EST. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruitment
of patients for the dose escalation study of lemzoparlimab in combination with pembrolizumab or rituximab is ongoing. Additional information on the clinical trial (NCT03934814) is available on <U>www.clinicaltrials.gov</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and AbbVie entered into a global strategic partnership to develop and commercialize
lemzoparlimab. Subject to <FONT STYLE="white-space:nowrap">pre-closing</FONT> conditions, both companies&nbsp;will be&nbsp;collaborating to further advance the clinical development of lemzoparlimab for&nbsp;the treatment of&nbsp;multiple
cancers&nbsp;globally and in China.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I-Mab Conference Call and Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and analysts are invited to join the conference call today at 8:30 a.m. ET using the following <FONT STYLE="white-space:nowrap">dial-in</FONT>
information: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">United States:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-888-346-8982</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">International:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-412-902-4272</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mainland&nbsp;China:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">400-120-1203</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hong Kong:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-905-945</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conference ID:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10149942</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live webcast and an archived replay of the conference call can be accessed on the Company&#146;s investor relations website
at <U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A telephone replay will be available approximately two hours after the
conclusion of the call by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-877-344-7529</FONT></FONT></FONT> (U.S.), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-412-317-0088</FONT></FONT></FONT> (International). The conference ID number for the replay is 10149942. The replay will be available through&nbsp;November 16, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CD47 and Lemzoparlimab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CD47 is a cell surface
protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a &#147;don&#146;t eat me&#148; signal to otherwise tumor-engulfing macrophages.&nbsp;CD47 antibody blocks this signal and enables macrophages to attack
tumor cells, making it a potentially promising cancer drug. However, development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47&nbsp;antibody to red blood
cells. In a scientific breakthrough, scientists <FONT STYLE="white-space:nowrap">at&nbsp;I-Mab&nbsp;have</FONT> discovered a unique CD47&nbsp;antibody, lemzoparlimab, that works efficiently to target tumor cells while exerting minimal untoward
effect on red blood cells, thus avoiding severe anemia. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822699dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lemzoparlimab&#146;s&nbsp;hematologic safety advantage and superb anti-tumor activities have been
demonstrated previously in a&nbsp;series of robust <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies.&nbsp;The results of the phase 1 clinical trial have provided further, clinical validation of this differentiation in patients with
cancer. <FONT STYLE="white-space:nowrap">I-Mab</FONT> continues to advance a&nbsp;combination study of lemzoparlimab with Keytruda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of solid tumors and with&nbsp;Rituxan<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;for the treatment of patients with lymphoma in the U.S., in addition to an ongoing clinical trial with patients with AML/MDS in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and AbbVie entered into a global strategic partnership to develop and commercialize
lemzoparlimab, including to design and conduct further clinical trials to evaluate lemzoparlimab in multiple cancers globally and in China. The collaboration is subject to certain <FONT STYLE="white-space:nowrap">pre-closing</FONT> conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of
immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10
clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s <FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies through internal R&amp;D and
global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities, world-class GMP manufacturing facility and
commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit
<U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the lemzoparlimab (TJC4) phase 1 trial, the potential implications of
clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical development, regulatory milestones and commercialization of lemzoparlimab (TJC4). Actual results may differ materially from
those indicated in the forward-looking statements as a result of various important factors, including but not limited to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the
clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved;
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug
development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to
complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those
risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks,
uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822699dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gigi Feng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Communications Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+86 21 6057 5785</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Investor Inquiries</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Burns McClellan, Inc. (Americas and Europe)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>The Piacente Group, Inc. (Asia)</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Steve Klass</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Emilie Wu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> sklass@burnsmc.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> emilie@thepiacentegroup.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Office line: +1 212 213 0006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Office line: +86 21 6039 8363</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g822699dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g822699dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M1,$E'WXB?F7_ !'O7=AL5#$1O'?L>I":DM#3KJ+"@ H * "@ H * "@ H *
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M7@K5?^%>S^&YKRW:8RAHI 6VJNX-@\9Z[OSJ_;1]KSI$JC+V7(V<U%\)_$$
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B.H* "@ H * "@ H * "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
